Rp-8-Br-cAMPS sodium

Cat. No.: HY-137640C: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Rp-8-Br-cAMPS sodium is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS sodium occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS sodium can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS sodium also inhibits insulin secretion.

For research use only. We do not sell to patients.

Rp-8-Br-cAMPS sodium Chemical Structure

CAS No. : 925456-59-3

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Rp-8-Br-cAMPS sodium:

Sp-8-Br-cAMPS sodium Get quote
Rp-8-Br-cAMPS Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All PKA Isoform Specific Products:

View All Isoforms

PKA PKAR

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Rp-8-Br-cAMPS (1 mM; 4-6 h) completely blocks the ability of 2-chloroadenosine (HY-W008344) to inhibit LAK cytotoxicity, and significantly reduces the inhibitory effect of 2-chloroadenosine (HY-W008344) on cytokine production^[1].
Rp-8-Br-cAMPS (50-100 μM; 2 min) inhibits insulin secretion in 832/13 cells (derived from INS-1 cells)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rp-8-Br-cAMPS (1 mg; intraperitoneal injection; 10 days) improves immune function in a mouse retrovirus infection model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Murine leukemia retrovirus RadLV-Rs treated male C57BL/6 mice^[3]
Dosage:	1 mg
Administration:	Intraperitoneal injection (i.p.); 10 days
Result:	Had no significant effect on the extent of lymphadenopathy and splenomegaly which is typical of RadLV-Rs retroviral infection. Strongly increased responses to the anti-CD3 mAb. Improved T cell responses.

Molecular Weight

446.15

Formula

C₁₀H₁₀BrN₅NaO₅PS

CAS No.

925456-59-3

SMILES

NC1=NC=NC2=C1N=C(Br)N2[C@H]3[C@H](O)[C@H](O4)[C@@H](CO[P@]4(S[Na])=O)O3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Raskovalova T, et al. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I). Immunol Res. 2006;36(1-3):91-9. [Content Brief]

[2]. Yang S, et al. Enhanced cAMP protein kinase A signaling determines improved insulin secretion in a clonal insulin-producing beta-cell line (INS-1 832/13). Mol Endocrinol. 2004 Sep;18(9):2312-20. [Content Brief]

[3]. Nayjib B, et al. In vivo administration of a PKA type I inhibitor (Rp-8-Br-cAMPS) restores T-cell responses in retrovirus-infected mice[J]. The Open Immunology Journal, 2008, 1(1).